| Literature DB >> 31720032 |
Magnus Wagenius1,2, Mattias Rydberg1, Marcin Popiolek3, Andreas Forsvall1, Johan Stranne4, Adam Linder2.
Abstract
INTRODUCTION: The aim of this study was to describe the complications of ureteroscopy (URS) and to investigate whether performing URS outside normal working hours leads to increased risk for clinically significant complications.Entities:
Keywords: complications; infection; monotherapy; stone; ureteric stone; ureteroscopy
Year: 2019 PMID: 31720032 PMCID: PMC6830489 DOI: 10.5173/ceju.2019.1951
Source DB: PubMed Journal: Cent European J Urol ISSN: 2080-4806
Patient characteristics and complications
| All patients (n = 567) | Patients not seeking medical within 14 days (n = 507) | Patients seeking medical care within 14 days (n = 60) | ||
|---|---|---|---|---|
| Age, Mean (±SD) | 55.0 (16.3) | 54.8 (16.1) | 56.7 (18.1) | |
| Diabetes | 12.2% (n = 69) | 12.4% (n = 63) | 10.0% (n = 6) | |
| Sex M:F ratio | 2.5:1 | 2.6:1 | 2:1 | |
| Charlson | 0 | 71.4% (n = 405) | 72.0% (n = 365) | 66.7% (n = 40) |
| Mortality | 28-d | – | – | 1.7% (n = 1) |
| Clavien-Dindo | 0 | 79.4% (n = 450) | 87.2% (n = 442) | 13.3% (n = 8) |
Stone characteristics and use of ureteral stent
| All patients (n = 567) | Patients not seeking medical care within 14 days (n = 507) | Patients seeking medical care within 14 days (n = 60) | ||
|---|---|---|---|---|
| Stone location | Distal | 58.4% (n = 331) | 58.4% (n = 296) | 58.3% (n = 35) |
| Stone size | ≤2 mm | 1.8%(n = 10) | 1.6% (n = 8) | 3.3% (n = 2) |
| Stone size at follow-up | No residual stones | 59.8% (n = 339) | 59.2% (n = 300) | 65.0% (n = 39) |
| Ureteral stent | Before | 15.9% (n = 90) | 15.8% (n = 80) | 16.7% (n = 10) |
| SFR | 90.7 (n = 515) | 90.3% (n = 458) | 88.3% (n = 53) |
SFR – stone-free rate
Figure 1Flowchart of re-admitted patients, divided into cause of re-admission. The distribution of patients with sequential sepsis-related organ failure assessment (SOFA) score ≥ is also shown.
Preoperative stone location in the upper urinary tract and residual stone size
| Distal third of ureter (n = 331) | Middle third of ureter (n = 97) | Proximal third of ureter (n = 75) | Renal pelvis (n = 58) | |
|---|---|---|---|---|
| SFR | 95.2% (n = 315) | 92.8% (n = 90) | 84.0% (n = 63) | 69.0% (n = 40) |
| No residual stones | 66.2% (n = 219) | 62.9% (n = 61) | 50.7% (n = 38) | 34.5% (n = 20) |
| ≤2 mm | 2.7% (n = 9) | 4.2% (n = 4) | 5.3% (n = 4) | 5.1% (n = 3) |
| >2 ≤4 mm | 0.9% (n = 3) | 3.1% (n = 3) | 6.7% (n = 5) | 10.4% (n = 6) |
| >4 ≤6 mm | 2.4% (n = 8) | 5.2% (n = 5) | 8.0% (n = 6) | 19.0% (n = 11) |
| >6 ≤10 mm | 2.1% (n = 7) | 1.0% (n = 1) | 6.7% (n = 5) | 5.1% (n = 3) |
| >10 mm | – | 1.0% (n = 1) | 1.3% (n = 1) | 6.8% (n = 4) |
| No follow-up | 23.6% (n = 78) | 20.6% (n = 20) | 18.7% (n = 14) | 17.2% (n = 10) |
| Patient no-show | 1.8% (n = 6) | 2.1% (n = 2) | 2.7 % (n = 2) | 1.7% (n = 1) |
| No longer in Scania | 0.3% (n = 1) | – | – | – |
SFR – stone-free rate
Preoperative stone size and stone-free rate
| Preoperativestone size | ≤2 mm (n = 10) | >2≤4 mm (n = 102) | >4≤6 mm (n = 183) | >6≤10 mm (n = 228) | >10 mm (n = 44) |
|---|---|---|---|---|---|
| SFR | 100% (n = 10) | 100% (n = 102) | 96.2% (n = 176) | 84.6% (n = 193) | 68.2% (n = 30) |
SFR – stone-free rate
Size of residual stones needed to be re-treated within 6 months
| Re-treated patients within 6 months (n = 20) | |
|---|---|
| Size of residual stone |
Preoperative urine culture and antibiotics treatment
| All patients (n = 567) | Patients not seeking medical care within 14 days (n = 507) | Patients seeking medical care within 14 days (n = 60) | |
|---|---|---|---|
| Positive urine culture | 15.9% (n = 90) | 14.0% (n = 71) | 31.7% (n = 19) |
| Preoperative antibiotics | 13.9% (n = 79) | 13.2% (n = 67) | 20.0% (n = 12) |
| Perioperative antibiotics | 60.1% (n = 341) | 59.4% (n = 301) | 66.7% (n = 40) |
| Postoperative antibiotics | 18.2% (n = 103) | 17.8% (n = 90) | 21.7% (n = 13) |
| Days of antibiotic treatment, Mean (range) | 2.3 (0–30) | 2.2 (0–30) | 2.8 (0–25) |
TMP/SMX – trimethoprim/sulfamethoxazole; E. Coli – Escherichia coli
Characteristics of patients with complications
| Patients seeking medical care within 14 days (n = 60) | Patients seeking medical care within 14 days, but not re-admitted (n = 20) | Patients seeking medical care within 14 days, re-admitted (n = 40) | |
|---|---|---|---|
| Age, Mean (±SD) | 56.7 (18.1) | 59.4 (17.6) | 55.4 (18.3) |
| Sex M:F Ratio | 2:1 | 4:1 | 1.5:1 |
| Cause of admission | |||
| Days until re-admission, Mean (range) | |||
| Blood culture drawn | 40.0% (n = 24) | – | 60.0% (n = 24) |
| Urine culture drawn | 63.3% (n = 38) | 40.0% (n = 8) | 75.0% (n = 30) |
| Positive culture | 21.7% (n = 13) | 10.0% (n = 2) | 27.5% (n = 11) |
| Antibiotics | 60.0% (n = 36) | 30.0% (n = 6) | 75.0% (n = 30) |
| ICU | 1.7% (n = 1) | – | 2.5% (n = 1) |
| SOFA score ≥2 | 20% (n = 12) | 5.0% (n = 1) | 27.5% (n = 11) |
TMP/SMX – trimethoprim/sulfamethoxazole
Figure 2Forest plot of univariate logistic regression analyses without significant P-value.
Univariate logistical regression analyses showing statistical significance
| P-value | OR | CI 95% | |
|---|---|---|---|
| On call personal to SFR | 0.141 | 0.222 | 0.606–33.378 |
| Not normal working hours to SFR | 0.141 | 0.222 | 0.606–33.378 |
| Stone location in ureter to SFR | <0.001 | 0.482 | 0.376–0.616 |
| Preoperative stone size to SFR | <0.001 | 0.885 | 0.852–0.920 |
| Postoperative ureteral stent to SFR | 0.002 | 0.413 | 0.237–0.721 |
| Clavien-Dindo to re-admission | <0.001 | 7.996 | 5.318–12.022 |
| Positive preoperative urine culture to readmission | 0.001 | 1.100 | 1.041–1.161 |
| Clavien-Dindo to mortality | 0.022 | 1.557 | 1.065–2.278 |
| Charlson Comorbidity index to mortality | <0.001 | 1.869 | 1.506–2.320 |
| SOFA score ≥2 to mortality | 0.023 | 15.667 | 1.460–168.074 |
| Clavien-Dindo to SOFA score ≥2 | 0.003 | 5.426 | 1.788–16.466 |
| Age to SOFA score ≥2 | 0.014 | 1.062 | 1.012–1.115 |
SFR – stone-free rate; SOFA – sequential sepsis-related organ failure assessment
Logistical regression analyses regarding hour of surgery, normal vs. call-time surgery, acute vs. elective surgery and flexible vs. semi-rigid ureteroscope and the risk of complications
| Model | Variable | OR (95% CI) | p-value |
|---|---|---|---|
| Time of day | 08.00–17.00 vs. other time of day | 0.5754 (0.2186; 1.5145) | 0.2630 |
| Age | 1.0230 (1.0085; 1.0377) | 0.0018 | |
| Men vs. women | 1.0781 (0.6562; 1.7713) | 0.7664 | |
| Night / Call | Night / Call vs. daytime | 0.5380 (0.2583; 1.1204) | 0.0977 |
| Age | 1.0224 (1.0080; 1.0371) | 0.0023 | |
| Men vs. women | 1.0870 (0.6612; 1.7868) | 0.7423 | |
| Acute | Acute vs. elective | 0.7539 (0.4400; 1.2919) | 0.3040 |
| Age | 1.0218 (1.0073; 1.0365) | 0.0032 | |
| Men vs. women | 1.0700 (0.6510; 1.7588) | 0.7895 | |
| Flexible | Flexible vs. standard | 1.6526 (0.9386; 2.9095) | 0.0818 |
| Age | 1.0224 (1.0078; 1.0371) | 0.0025 | |
| Men vs. women | 1.1227 (0.6815; 1.8494) | 0.6496 |
Figure 3Recevier operating characteristic (ROC) curve describing sensitivity + specificity vs. age for risk of complications and ROC curve.
| Variable | Updated Charlson Score |
|---|---|
| Charlson comorbidity | |
| Myocardial infarction | 0 |
| Congestive heart failure | 2 |
| Peripheral vascular disease | 0 |
| Cerebrovascular disease | 0 |
| Dementia | 2 |
| Chronic pulmonary disease | 1 |
| Rheumatologic disease | 1 |
| Peptic ulcer disease | 0 |
| Mild liver disease | 2 |
| Diabetes without chronic complications | 0 |
| Diabetes with chronic complications | 1 |
| Hemiplegia or paraplegia | 2 |
| Renal disease | 1 |
| Any malignancy, including leukaemia /lymphoma | 2 |
| Moderate or severe liver disease | 4 |
| Metastatic solid tumour | 6 |
| AIDS/HIV | 4 |
| Maximum comorbidity score | 24 |
AIDS – acquired immunodeficiency syndrome; HIV – human immunodeficiency virus
| Grade I | Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. |
| Grade II | Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included. |
| Grade III | Requiring surgical, endoscopic or radiological intervention. |
| Grade IV | Life-threatening complication (including CNS complications) requiring IC/ICU-management. |
| Grade V | Death of a patient. |